Cross reactivity of epigenetic biomarkers will be studied in more than a dozen additional cancer types.
Orion Genomics initiated a collaboration with Mayo Clinic to study the clinical utility of Orion’s breast cancer screening tests. These tests are based on epigenetic biomarkers that were discovered using Orion’s DNA methylation technologies.
Under the collaboration, physicians and scientists at Mayo Clinic and Orion will validate the tumor specificity of Orion’s breast cancer biomarkers by analyzing the cross reactivity of these epigenetic biomarkers in more than a dozen additional cancer types.
Utilizing unique epigenetic biomarkers, Orion Genomics says that it is developing cancer screening tests that are designed to work in blood, tissue, and other biological samples for the early detection of breast and other common cancers, including lung, ovarian, and colon cancers. To date, Orion reports that it has discovered and validated in independent patient panels over 50 novel breast cancer biomarkers.
